EarningsQ3 2026 Earnings Report

Olympus (OLY) Q3 2026 Earnings Report

1 Followers

Previous Report: Q2 2026

Next Report: Q4 2026

DE:OLY Q3 2026 EPS Results

Actual EPS€0.07

Consensus EPS€0.13

Beat/MissMissed by -€0.06

One Year Ago EPS€0.14

DE:OLY Q3 2026 Revenue Results

Actual Revenue€1.51B

Expected Revenue€1.50B

Beat/MissBeat by +€9.30M

YoY Revenue Growth+2.78%

Earnings Announcement Details

QuarterQ3 2026

Date02/13/2026

TimeBefore Open

Conference CallFriday, February 13, 2026

DE:OLY Upcoming Earnings

Olympus's next earnings date is estimated for November 6, 2026, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:OLY Q3 2026 Earnings Call

0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026

Earnings Call Date:Feb 13, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call balanced significant near-term operational and regulatory challenges (FDA observations, product ship holds, one-off gross margin/COGS impacts, and increased restructuring provisioning) against clear signs of stabilization and management actions (China recovery, majority of products released, leadership changes, disciplined commercial remediation and maintained mid-term targets). Management emphasized these are addressable, one-off or execution-related issues and reiterated long-term margin and growth ambitions, but material short-term impacts keep the tone cautious.

Company Guidance

Management revised constant‑currency revenue guidance down ~2% and framed near‑term outlook as a range (reflecting the dynamic timing of product releases), while reaffirming its midterm targets of mid‑single‑digit revenue growth and a 20%+ operating margin; key metrics called out included the company’s “3–4–5” mid‑range modeling with 100+ basis points of margin improvement annually from FY27, inspections at 8 facilities (U.S., Europe, Japan) with ~70% of ship‑hold products already released and ~30% still being remediated, an expected Q4 revenue impact from ship holds of about JPY 18 billion, structural‑reform costs provisioned at JPY 31 billion (revised up from JPY 12 billion) with ~90% booked this fiscal year and the previously announced JPY 24 billion reduction effect unchanged, China showing a recovery (management cited roughly 6% Q3 growth and expects mid‑single‑digit market growth), and that one‑time COGS pressure from disposals/field corrective actions drove the gross‑margin hit rather than a fundamental mix shift.

China: Early Signs of Recovery

After several quarters of double-digit declines, China showed a turnaround with approximately 5–6% growth quarter-over-quarter following tightened go-to-market focus, local investments and weekly pipeline oversight.

Majority of Ship-Held Products Returned to Market

Management reported that ~70% of products placed on ship hold have been released back into markets after patient-safety reviews; ~30% remain under remediation.

Mid-term Plan and Margin Commitment Intact

Management reiterated the midterm '3,4,5' plan and the target of >100 basis points of annual margin improvement beginning FY27, maintaining the longer-term goal of mid-single-digit revenue growth and 20%+ operating margin.

Leadership Actions to Drive Execution

New senior appointments (new President of China Rosa Chen, global operations lead David Shan, and continued CTO leadership) aimed at strengthening go-to-market execution, operations and R&D; management emphasized building Japanese leadership depth as well.

Commercial Execution Plan for U.S. GI

Management identified U.S. GI underperformance as an execution/pipeline conversion issue (not a competitiveness problem) and outlined disciplined pipeline management and oversight actions to restore growth, expressing confidence in returning to growth in Q4.

Guidance Presented Transparently as Ranges

Company moved to range-based guidance to reflect dynamic factors (product releases timing, pipeline conversion) and stated ranges do not assume additional ship holds.

DE:OLY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 06, 2026	2027 (Q2)	0.12 / -	0.104	―
Aug 07, 2026	2027 (Q1)	0.05 / 0.10	0.048	107.41% (+0.05)
May 12, 2026	2026 (Q4)	0.04 / 0.13	0.223	-43.20% (-0.10)
Feb 13, 2026	2026 (Q3)	0.13 / 0.07	0.143	-47.50% (-0.07)
Nov 07, 2025	2026 (Q2)	0.12 / 0.10	0.172	-39.38% (-0.07)
Aug 08, 2025	2026 (Q1)	0.10 / 0.05	0.076	-36.47% (-0.03)
May 13, 2025	2025 (Q4)	0.14 / 0.22	0.07	220.51% (+0.15)
Feb 14, 2025	2025 (Q3)	0.20 / 0.14	0.105	35.59% (+0.04)
Nov 08, 2024	2025 (Q2)	0.19 / 0.17	-0.106	262.18% (+0.28)
Aug 07, 2024	2025 (Q1)	0.08 / 0.08	1.185	-93.60% (-1.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed